勃林格殷格翰与再鼎医药宣布达成战略合作，将共同开发靶向Dll3的T细胞衔接双特异性抗体与抗体偶联药物的联合疗法。该创新疗法旨在治疗小细胞肺癌及其他神经内分泌癌患者。
此次合作将整合勃林格殷格翰在肿瘤免疫治疗领域的专业优势与再鼎医药在中国市场的临床开发及商业化能力。双方计划通过联合疗法探索新的治疗模式，为患者提供更具突破性的治疗方案。
神经内分泌癌是一类罕见且治疗难度较大的恶性肿瘤，小细胞肺癌作为其中最具侵袭性的亚型，长期以来面临治疗选择有限的挑战。靶向Dll3的创新疗法有望为这类患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.